Aller au contenu principal
Fermer
  2. Aide
  2. Aide

Transgene Reports First Promising Efficacy Results with TG4001 in Combination with Avelumab in HPV-Positive Cancer at ESMO 2019
information fournie par Boursorama 30/09/2019 à 17:45

- Three of six patients showed durable responses (patients treated with the recommended Phase 2 dose)1
- Combination therapy results in changes in tumor microenvironment shifting immune status from "cold" to "hot"
- Clinical trial conducted in collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer

Conference call scheduled on October 3, 2019 at 2:30 p.m. CET

Strasbourg, France, September 30, 2019, 5:45 p.m. CET - Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, today presented promising safety and efficacy data of TG4001 in combination with avelumab (BAVENCIO®), a human anti-programmed death ligand (PD-L1) antibody, in HPV-16+ recurrent or metastatic malignancies (including oropharyngeal cancers). These Phase 1b data have been presented in a poster (#1210P) at the European Society for Medical Oncology (ESMO) 2019 Congress in Barcelona, Spain. TG4001 is a therapeutic vaccine based on a Vaccinia vector (MVA), which is engineered to express HPV-16 antigens (E6 & E7). It has been administered to more than 300 individuals in previous trials, demonstrating good safety, significant HPV clearance rate and promising efficacy results.

Valeurs associées

TRANSGENE
0,8290 EUR Euronext Paris -0,72%
Le présent contenu est proposé par Boursorama. Cet article ou cette vidéo ne doivent en aucun cas s'apparenter à un conseil en investissement ou une recommandation d'acheter, de vendre ou de continuer à détenir un investissement. Boursorama ne saurait être tenue responsable d'une décision d'investissement ou de désinvestissement sur la base de cet article ou de cette vidéo.

0 commentaire

Signaler le commentaire

Fermer

A lire aussi

Mes listes

valeur

dernier

var.
CAC 40
8 035,67 +0,68%
SOITEC
155,1 +8,35%
Pétrole Brent
109,08 -1,66%
NANOBIOTIX
35,78 -7,02%
HAFFNER ENERGY
0,1474 +6,35%
Chargement...

Pages les plus populaires

L'offre BoursoBank